Aggressive de-escalation of chemoradiation after surgery in patients with HPV-associated OPSCC led to similar disease control and improved quality of life and safety profile compared with historical controls, according to data presented at the ASTRO 59th Annual Meeting.
Small study also showed that pembrolizumab does not significant impair radiation or chemotherapy dosing.
Disease-specific survivorship care plans (SCPs) for head and neck cancer support a successful transition to a healthy lifestyle after curative intent therapy of larynx and oral cavity/pharynx cancer.
A literature review noted improvements in quality of life after patients were coached and educated following radiotherapy for HPV-associated oropharyngeal cancers.
Clinical practice guideline from ASTRO addresses optimal radiation doses and fractionation schedules, integrating therapies, and induction chemotherapy for oropharyngeal squamous cell carcinoma (OPSCC).
Protein produced by chronically infected cells in persons with HPV16 infection serves as a biomarker for risk of cancer of the oropharynx.
The impact of oral squamous cell carcinoma (OSCC) diagnosis and treatment on sexual behavior and relationship stress with respect to HPV status was evaluated in this study. Participants included patients with HPV-positive and HPV-negative disease, as well as partners.
Patients with oropharyngeal tumors that harbor HPV16 have higher 5-year survival and lower recurrence rates than patients with tumors that harbor other HPV strains or are HPV-negative.
Transoral robotic surgery (TORS) with or without radiation therapy or chemotherapy is an effective treatment option for patients with oropharyngeal cancer regardless of their p16 status.
Despite a higher risk for HPV-negative orophayngeal squamous cell carcinoma (OPSCC), poor oral health appears to be associated with OPSCC regardless of HPV status.
The incidence of oropharyngeal squamous cell carcinoma is increasing among older patients residing in the United States, likely due to the increase in HPV-associated malignancies.
Cervical cancer, and oropharyngeal cancers in men, account for most HPV-associated cancers.
Although HPV vaccination is expected to decrease the cancer burden from HPV across all racial and ethnic groups, some disparities are expected to persist and widen if their causes are not addressed, including lack of access to screening, timely diagnoses, and treatment.
Staging by Lymph Node Categories Shown to Better Predict Survival in Patients With Oropharyngeal CancerMarch 15, 2016
The current staging system for oropharyngeal cancer does not adequately differentiate HPV-positive from HPV-negative OPC. These researchers suggest regional OPC lymph node (N) categories and nasopharyngeal N categories might be more useful in staging HPV-positive OPC.
Posttreatment imaging at 3 months and physical examinations during the 6 months following treatment can detect most recurrences in patients treated with definitive radiation therapy for HPV-associated oropharyngeal cancer.
Among patients treated for oropharyngeal cancers linked to human papillomavirus (HPV) infection, at least 1 HPV-infection antibody could help identify those patients at risk for a recurrence of the cancer.
HPV-positive oropharyngeal cancer prevalence varies between Western Europe and Eastern Europe, according to study data.
Depression is a significant predictor of 5-year survival and recurrence in patients with head and neck cancer. These findings represent one of the largest studies to report on the impact of depression on cancer survival.
Oropharyngeal cancer patients with detectable traces of human papillomavirus type 16 (HPV16) in their saliva after cancer treatment are at an increased risk for recurrence.
Patients with oropharyngeal cancer who were found to have detectable traces of human papillomavirus type 16 (HPV16) in their saliva.
The presence of certain human papillomavirus (HPV)-16 antibodies in the blood is associated with improved survival rates for patients with HPV-related oropharyngeal carcinoma.
Detection of human papillomavirus (HPV)16 DNA in oral rinses following treatment for HPV-positive oropharyngeal carcinoma could be a potential tool for long-term tumor surveillance, a study concluded at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Human papillomavirus (HPV) vaccine may be a cost-effective approach for preventing squamous cell oropharyngeal cancer.
Mixed views have been expressed in relation to explaining the causal role of HPV in oropharyngeal cancer.
Human papillomavirus (HPV)-positive oropharyngeal cancer may not require neck surgery after receiving radiation therapy and chemo.
Physicians have developed blood and saliva tests that help accurately predict recurrences of HPV-linked oral cancers in a substantial number of patients. The tests screen for DNA fragments of the HPV shed from cancer cells lingering in the mouth or other parts of the body.
Human papillomavirus (HPV) positivity is associated with improved survival after disease progression, according to a study.
Reduced-dose intensity-modulated radiotherapy after complete clinical responses to induction chemotherapy for operable stage III/IVA, human papillomavirus (HPV)-positive head and neck cancer appears to be safe and might improve patients' quality of life.
ANAHEIM, CALIFORNIA—Among oropharyngeal patients receiving radiotherapy, gabapentin improved pain management and reduced weight loss, which potentially prevents the need for placement of a gastrostomy tube, according to a study presented at the Oncology Nursing Society (ONS) 39th Annual Congress.
Most oropharyngeal cancers in the United States diagnosed between 1995 and 2005 were positive for human papillomavirus (HPV), according to a study.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- A Witness to Letting Go: Nursing Care at the End of Life
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Androgen-Deprivation Therapy for Prostate Cancer May Cause Nocturia, Sleep Disturbance
- USPSTF Rates Ovarian Cancer Screening a D for Asymptomatic, Low-Risk Women
- Colorectal Cancer Screening Rate Increased by Digital Self-Ordering
- Presence of Iris Pigmented Lesions Indicates Melanoma Risk
- A Witness to Letting Go: Nursing Care at the End of Life
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|